Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE: 600329)
Health Care · Pharmaceuticals · CN
CN¥35.35
-2.56% today · -23.5% 1Y
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE: 600329) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.51B and employs 3,890 people.
Over the last twelve months the share price has lost 23.5%, trading between 34.70 and 50.97.
Tweenvest scores Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited across four factors: quality 82/100, value 47/100, growth 24/100, dividend 77/100. Its strongest factor is quality.
600329 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.51B
- Revenue (TTM)
- $695.06M
- P/E
- 31.99
- EPS
- 1.10
- Dividend yield
- 12.90%
- Beta (5Y)
- 0.53
- 52-week high
- CN¥50.97
- 52-week low
- CN¥34.70
- Avg volume (3M)
- —
- Shares outstanding
- 770.09M
- Employees
- 3,890
- Next earnings
- —
About Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, along with its subsidiaries, primarily manufactures and markets traditional Chinese medicine, Western pharmaceuticals, and various healthcare products within the People's Republic of China. Its business activities are structured into two distinct divisions: Chinese Medicine and Western Medicine. The company's operations extend beyond its core offerings to include the production and distribution of Chinese, Western, and biological pharmaceutical items. It also engages in the wholesale and retail trade of medicines, biochemical pharmaceutical products, and everyday consumer goods, in addition to managing hospitals. Furthermore, Tianjin Pharmaceutical Da Ren Tang provides a comprehensive suite of services such as logistics, inventory management, equipment installation, and drug processing. It also offers pharmaceutical inspection, testing, and advisory services. In terms of its commercial model, the company supplies its proprietary branded medicinal products directly to wholesalers. Conversely, it acquires pharmaceuticals marketed under other brands from distributors, subsequently reselling these to other wholesale clients. Established in 1992 and based in Tianjin, People's Republic of China, the company was previously known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited before adopting its current name in May 2022.
- ISIN
- CNE000001808
- Founded
- 1915
- Listed since
- Jun 6, 2001
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.